U.S. Markets close in 5 hrs 11 mins

Lipocine Inc. (LPCN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.08-0.02 (-0.49%)
As of 10:30AM EDT. Market open.
People also watch
MRNSSCYXEVOKTNXPTRIL

Lipocine Inc.

675 Arapeen Drive
Suite 202
Salt Lake City, UT 84108
United States
801-994-7383
http://www.lipocine.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees16

Key Executives

NameTitlePayExercisedAge
Dr. Mahesh V. Patel Ph.d.Co-Founder, Chairman, Chief Exec. Officer and Pres638.7kN/A60
Mr. Morgan R. Brown CPA, MBAChief Financial Officer, Exec. VP and Corp. Sec.420.24kN/A49
Dr. William I. Higuchi Ph.D.Chief Scientific ConsultantN/AN/A86
Mr. Gregory B. BassChief Commercial Officer and Exec. VPN/AN/A43
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing that has completed Phase 3 testing. The company’s pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase 2 testing; and LPCN 1107, which has completed Phase 2 testing for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Corporate Governance

Lipocine Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.